Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics

Core Insights - Aquestive Therapeutics reported a revenue of $11.87 million for Q4 2024, reflecting a year-over-year decline of 10.2% and an EPS of -$0.19 compared to -$0.12 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $13.5 million by 12.11%, while the EPS also missed the consensus estimate of -$0.14 by 35.71% [1] Revenue Breakdown - Manufacture and supply revenue was $10.66 million, below the average estimate of $11.38 million, representing a year-over-year decline of 3% [4] - License and royalty revenue was $0.83 million, significantly lower than the average estimate of $1.86 million, indicating a year-over-year decrease of 55.6% [4] - Co-development and research fees amounted to $0.27 million, compared to the average estimate of $0.43 million, reflecting an 18.2% year-over-year decline [4] - Proprietary product sales, net, were $0.10 million, below the average estimate of $0.20 million [4] Stock Performance - Shares of Aquestive Therapeutics have decreased by 11.1% over the past month, while the Zacks S&P 500 composite has declined by 4.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]